Acute Effects of Oculomotor Exercises on Posturography and Gait Analysis Parameters in Regular Exercisers (OMEX-PG)

July 16, 2026 updated by: Vedat Kavak, Ege University

The Acute Effects of Oculomotor Exercises on Static Posturography and Gait Analysis Parameters in Regular Exercisers

This study aims to investigate the acute effects of a single-session oculomotor exercise program on static posturography and gait analysis parameters in healthy individuals who exercise regularly. Postural control and gait are complex sensorimotor functions that depend on the integration of visual, vestibular, somatosensory, and motor systems. Eye movements and gaze stabilization may contribute to postural orientation and locomotor control by influencing visual-vestibular integration, head-eye coordination, and sensorimotor adaptation. However, the immediate effects of short-duration oculomotor exercise programs on postural sway and gait-related parameters in regular exercisers have not been fully clarified.

This study is designed as a single-group, within-session, pre-post interventional study. Participants will undergo baseline assessments, complete a single session of oculomotor exercises, and then be reassessed after the intervention in the same testing session. The study population will consist of healthy adults who exercise regularly and meet the predefined eligibility criteria. Individuals with musculoskeletal injury, neurological or vestibular disorders, visual conditions that may affect balance or eye movement performance, or any condition limiting participation in the testing procedures will be excluded.

Static posturography will be performed using the HUR SmartBalance BTG4 system to evaluate postural sway under different sensory conditions. Measurements will be obtained during quiet standing with eyes open on a firm surface, eyes closed on a firm surface, eyes open on a foam surface, and eyes closed on a foam surface. The main posturography variables will include sway area, trace length, sway velocity, lateral sway, and anterior-posterior sway.

Gait analysis will be performed before and after the intervention using the DIERS Pedogait system. Spatiotemporal, phase-related, and center-of-pressure-based gait parameters will be recorded. These parameters may include step length, stride length, step time, stride time, track width, cadence, stance phase, swing phase, double support, pre-swing, and center-of-pressure-related gait variables.

The oculomotor exercise program will include three main components: extraocular eye movement exercises, vestibulo-ocular and cervico-ocular gaze stabilization exercises, and accommodation exercises. During extraocular eye movement exercises, participants will be asked to follow a visual target with eye movements while keeping the head stable. During gaze stabilization exercises, participants will maintain visual fixation on a target while performing controlled head movements and walking steps. During accommodation exercises, participants will alternate focus between a near target and a distant target. The exercises will be performed at different speeds to stimulate oculomotor control, gaze stabilization, and visual focusing mechanisms.

The primary outcome of the study is the change in sway area from baseline to the post-intervention assessment. Secondary outcomes include changes in other static posturography parameters and gait analysis variables. By evaluating both postural sway and gait-related outcomes, this study aims to provide preliminary evidence on whether a short oculomotor exercise session may produce immediate changes in postural control and walking characteristics in regular exercisers.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Active, not recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
51

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey (Türkiye)
    • Bornova
      • Izmir, Bornova, Turkey (Türkiye), 35100
        • Ege University Faculty of Medicine, Department of Sports Medicine

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Healthy adults aged 18 to 50 years
  • Regular participation in exercise
  • Ability to walk independently without an assistive device
  • Ability to understand and follow the study procedures
  • Ability to complete the oculomotor exercise program, static posturography assessment, and gait analysis
  • Provision of written informed consent

Exclusion Criteria:

  • Acute musculoskeletal injury or pain that could affect balance, gait, or exercise performance
  • Neurological disease that could affect balance, gait, or oculomotor control
  • Vestibular disorder or current symptoms of dizziness or vertigo
  • Visual or ocular disorder that could affect visual fixation, eye movements, or balance assessment
  • Use of medication that could affect balance, coordination, alertness, or gait
  • Inability to walk independently
  • Inability to complete the oculomotor exercise intervention or assessment procedures
  • Any medical condition considered by the investigator to interfere with safe participation or the validity of the assessments

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Oculomotor Exercise Group
Participants in this single-arm group will receive a single-session oculomotor exercise program. Static posturography and gait analysis assessments will be performed before and after the intervention within the same testing session.
Behavioral: Oculomotor Exercise Program
The intervention consists of a single-session oculomotor exercise program including extraocular eye movement exercises, vestibulo-ocular and cervico-ocular gaze stabilization exercises, and accommodation exercises. During extraocular eye movement exercises, participants will follow a visual target with eye movements while keeping the head stable. During gaze stabilization exercises, participants will maintain visual fixation on a target while performing controlled head movements and walking steps. During accommodation exercises, participants will alternate visual focus between a near target and a distant target. Exercises will be performed at different speeds within the same session.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change From Baseline in Sway Area Under Four Sensory Conditions
Time Frame: Baseline and 15 minutes after the intervention
Sway area was assessed during 30 seconds of quiet standing using the HUR SmartBalance BTG4 static posturography system. Measurements were obtained under four sensory conditions: eyes open on a firm surface, eyes closed on a firm surface, eyes open on a foam surface, and eyes closed on a foam surface. Condition-specific sway area values were expressed using the same unit of measure (mm²). The change from baseline to 15 minutes after the single-session oculomotor exercise intervention was evaluated separately for each sensory condition..
Baseline and 15 minutes after the intervention

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Change From Baseline in Trace Length Under Four Sensory Conditions
Time Frame: Baseline and 15 minutes after the intervention
Trace length was assessed during 30 seconds of quiet standing using the HUR SmartBalance BTG4 static posturography system. Measurements were obtained under eyes-open firm-surface, eyes-closed firm-surface, eyes-open foam-surface, and eyes-closed foam-surface conditions. Condition-specific trace length values were expressed using the same unit of measure (mm). The change from baseline to 15 minutes after the intervention was evaluated separately for each sensory condition.
Baseline and 15 minutes after the intervention
Change From Baseline in Single-Support Phase Percentage
Time Frame: Baseline and 15 minutes after the intervention
Right and left single-support phase values were assessed during barefoot treadmill walking at 3 km/h using the DIERS Pedogait system. Single support was expressed as a percentage of the gait cycle. The change from baseline to 15 minutes after the intervention was evaluated separately for each side.
Baseline and 15 minutes after the intervention
Change From Baseline in Sway Velocity Under Four Sensory Conditions
Time Frame: Baseline and 15 minutes after the intervention
Sway velocity was assessed during 30 seconds of quiet standing using the HUR SmartBalance BTG4 static posturography system. Measurements were obtained under eyes-open firm-surface, eyes-closed firm-surface, eyes-open foam-surface, and eyes-closed foam-surface conditions. Condition-specific sway velocity values were expressed using the same unit of measure (mm/s) . The change from baseline to 15 minutes after the intervention was evaluated separately for each sensory condition.
Baseline and 15 minutes after the intervention
Change From Baseline in Mediolateral Sway Under Four Sensory Conditions
Time Frame: Baseline and 15 minutes after the intervention
Mediolateral sway was assessed during 30 seconds of quiet standing using the HUR SmartBalance BTG4 static posturography system. Measurements were obtained under eyes-open firm-surface, eyes-closed firm-surface, eyes-open foam-surface, and eyes-closed foam-surface conditions. Condition-specific mediolateral sway values were expressed using the same unit of measure (mm). The change from baseline to 15 minutes after the intervention was evaluated separately for each sensory condition.
Baseline and 15 minutes after the intervention
Change From Baseline in Anteroposterior Sway Under Four Sensory Conditions
Time Frame: Baseline and 15 minutes after the intervention
Anteroposterior sway was assessed during 30 seconds of quiet standing using the HUR SmartBalance BTG4 static posturography system. Measurements were obtained under eyes-open firm-surface, eyes-closed firm-surface, eyes-open foam-surface, and eyes-closed foam-surface conditions. Condition-specific anteroposterior sway values were expressed using the same unit of measure (mm). The change from baseline to 15 minutes after the intervention was evaluated separately for each sensory condition.
Baseline and 15 minutes after the intervention
Change From Baseline in Romberg Quotient on Firm and Foam Surfaces
Time Frame: Baseline and 15 minutes after the intervention
The Romberg quotient was calculated using static posturography measurements obtained during eyes-open and eyes-closed standing. Separate Romberg quotient values were calculated for the firm and foam surfaces using the HUR SmartBalance BTG4 system. Both values were expressed using the same unit of measure. The change from baseline to 15 minutes after the intervention was evaluated separately for each surface.
Baseline and 15 minutes after the intervention
Change From Baseline in Step Length
Time Frame: Time Frame: Baseline and 15 minutes after the intervention
Right and left step length values were assessed during barefoot treadmill walking at 3 km/h using the DIERS Pedogait system. Right and left values represented the same outcome variable and were expressed using the same unit of measure. The change from baseline to 15 minutes after the intervention was evaluated separately for each side.
Time Frame: Baseline and 15 minutes after the intervention
Change From Baseline in Track Width
Time Frame: Baseline and 15 minutes after the intervention
Track width was assessed during barefoot treadmill walking at 3 km/h using the DIERS Pedogait system. Track width represents the mediolateral distance between consecutive foot placements. The change from baseline to 15 minutes after the intervention was evaluated.
Baseline and 15 minutes after the intervention
Change From Baseline in Stride Length
Time Frame: Baseline and 15 minutes after the intervention
Right and left stride length values were assessed during barefoot treadmill walking at 3 km/h using the DIERS Pedogait system. Right and left values represented the same outcome variable and were expressed using the same unit of measure. The change from baseline to 15 minutes after the intervention was evaluated separately for each side.
Baseline and 15 minutes after the intervention
Change From Baseline in Step Time
Time Frame: Baseline and 15 minutes after the intervention
Right and left step time values were assessed during barefoot treadmill walking at 3 km/h using the DIERS Pedogait system. Right and left values represented the same outcome variable and were expressed using the same unit of measure. The change from baseline to 15 minutes after the intervention was evaluated separately for each side.
Baseline and 15 minutes after the intervention
Change From Baseline in Stride Time
Time Frame: Baseline and 15 minutes after the intervention
Right and left stride time values were assessed during barefoot treadmill walking at 3 km/h using the DIERS Pedogait system. Right and left values represented the same outcome variable and were expressed using the same unit of measure. The change from baseline to 15 minutes after the intervention was evaluated separately for each side.
Baseline and 15 minutes after the intervention
Change From Baseline in Stance Phase Percentage
Time Frame: Baseline and 15 minutes after the intervention
Right and left stance phase values were assessed during barefoot treadmill walking at 3 km/h using the DIERS Pedogait system. Stance phase was expressed as a percentage of the gait cycle. The change from baseline to 15 minutes after the intervention was evaluated separately for each side.
Baseline and 15 minutes after the intervention
Change From Baseline in Pre-Swing Phase Percentage
Time Frame: Baseline and 15 minutes after the intervention
Right and left pre-swing phase percentages were assessed during barefoot treadmill walking at 3 km/h using the DIERS Pedogait system. Pre-swing was expressed as a percentage of the gait cycle. The change from baseline to 15 minutes after the intervention was evaluated separately for each side.
Baseline and 15 minutes after the intervention
Change From Baseline in Double-Support Phase Percentage
Time Frame: Baseline and 15 minutes after the intervention
Right and left double-support phase percentages were assessed during barefoot treadmill walking at 3 km/h using the DIERS Pedogait system. Double support was expressed as a percentage of the gait cycle. The change from baseline to 15 minutes after the intervention was evaluated separately for each side.
Baseline and 15 minutes after the intervention
Change From Baseline in Swing Phase Percentage
Time Frame: Baseline and 15 minutes after the intervention
Right and left swing phase values were assessed during barefoot treadmill walking at 3 km/h using the DIERS Pedogait system. Swing phase was expressed as a percentage of the gait cycle. The change from baseline to 15 minutes after the intervention was evaluated separately for each side.
Baseline and 15 minutes after the intervention
Change From Baseline in Load Response Phase Percentage
Time Frame: Baseline and 15 minutes after the intervention
Right and left load response phase values were assessed during barefoot treadmill walking at 3 km/h using the DIERS Pedogait system. Load response was expressed as a percentage of the gait cycle. The change from baseline to 15 minutes after the intervention was evaluated separately for each side.
Baseline and 15 minutes after the intervention
Change From Baseline in Single-Support Phase Percentage
Time Frame: Baseline and 15 minutes after the intervention
Right and left single-support phase percentages were assessed during barefoot treadmill walking at 3 km/h using the DIERS Pedogait system. Single support was expressed as a percentage of the gait cycle. The change from baseline to 15 minutes after the intervention was evaluated separately for each side.
Baseline and 15 minutes after the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ege University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 2, 2025

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
September 5, 2026

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 11, 2026

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
July 12, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 16, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
July 21, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
July 21, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 16, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • EUTF-OKULO-33058

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared due to institutional and ethical restrictions and because the informed consent process did not include permission for public sharing of individual-level data.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Exercise

Clinical Trials on Oculomotor Exercise Program

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings